Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem cell transplant (auto-PBSCT) predicts progression-free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP (dexamet...

Descripción completa

Detalles Bibliográficos
Autores principales: Kersten, Marie José, Driessen, Julia, Zijlstra, Josée M., Plattel, Wouter J., Morschhauser, Franck, Lugtenburg, Pieternella J., Brice, Pauline, Hutchings, Martin, Gastinne, Thomas, Liu, Roberto, Burggraaff, Coreline N., Nijland, Marcel, Tonino, Sanne H., Arens, Anne I.J., Valkema, Roelf, van Tinteren, Harm, Lopez-Yurda, Marta, Diepstra, Arjan, De Jong, Daphne, Hagenbeek, Anton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018114/
https://www.ncbi.nlm.nih.gov/pubmed/32273476
http://dx.doi.org/10.3324/haematol.2019.243238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018114/
https://www.ncbi.nlm.nih.gov/pubmed/32273476
http://dx.doi.org/10.3324/haematol.2019.243238

Ejemplares similares